Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00181168 · ClinicalTrials.gov registry record · Phase 2
Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
NCT00181168: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT00181168 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 63 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00181168, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
Study Summary
The purpose of this study is to determine \[for patients with previously treated well-differentiated thyroid cancer and evidence of residual disease based on serum thyroglobulin (Tg) level\] whether positron emission tomography-computed tomography (PET-CT) fusion scanning performed after recombinant thyroid-stimulating hormone (TSH) (rTSH, thyrotropin alfa for injection) will be more sensitive for the detection of disease sites than PET-CT scanning without rTSH. The study will also determine if this information will significantly alter the therapeutic approach in some patients.
Interventions
- DRUG Euthyroid Group
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2001-03 |
| Est. Completion | 2003-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00181168
The ClinicalTrials.gov registry entry for NCT00181168 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Euthyroid Group is the first listed.
NCT00181168 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00181168 about?
NCT00181168 is a clinical study titled "Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer". The purpose of this study is to determine \[for patients with previously treated well-differentiated thyroid cancer and evidence of residual disease based on serum thyroglobulin (Tg) level\] whether positron emission tomography-computed tomography (PET-CT) fusion scanning performed after recombinant...
What is the current status of trial NCT00181168?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2001-03. Estimated completion is 2003-09.
What interventions are being tested in trial NCT00181168?
The interventions under investigation include: Euthyroid Group (DRUG).
Who is sponsoring clinical trial NCT00181168?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.